Soluble VE-cadherin in Prediction and Diagnosis of Early Postoperative Hypoxemia After Cardiopulmonary Bypass
Launched by ZHUAN ZHANG · Dec 4, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years;
- • Underwent cardiac surgery using CPB technology.
- Exclusion Criteria:
- • Patient's lack of consent to participate;
- • Presence of abnormal liver, kidney or other organ function;
- • Pulmonary inflammation, chronic obstructive pulmonary disease or tumors;
- • Underwent cardiac surgery without CPB technology;
- • Postoperative need for extracorporeal membrane oxygenation support.
About Zhuan Zhang
Zhuan Zhang is a dedicated clinical trial sponsor specializing in the development and management of innovative therapeutic solutions across various medical fields. With a commitment to advancing healthcare, Zhuan Zhang leverages cutting-edge research methodologies and a robust network of clinical partnerships to facilitate the efficient execution of trials. The organization emphasizes patient safety, regulatory compliance, and the generation of high-quality data to support the successful introduction of new treatments. By fostering collaboration and harnessing scientific expertise, Zhuan Zhang aims to contribute meaningfully to the improvement of patient outcomes and the overall advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yangzhou, Jiangsu, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials